A- A A+


A guide for addiction treatment clinicians and programs working to treat patients with substance use disorders safely and effectively during the COVID-19 pandemic. (ASAM – American Society of Addiction Medicine, Juni 2021)


“You know, we can change the services to suit the circumstances of what is happening in the world”: a rapid case study of the COVID-19 response across city centre homelessness and health services in Edinburgh, Scotland. 

Parkes, T., Carver, H., Masterton, W. et al. 

Harm Reduct J 18, 64 (2021). doi.org/10.1186/s12954-021-00508-1


Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. 

Dunn KE, Brooner RK, Stoller KB. 

J Subst Abuse Treat. 2021;121:108197. doi:10.1016/j.jsat.2020.108197


Opioid use disorder and health service utilization among COVID-19 patients in the US: A nationwide cohort from the Cerner Real-World Data

Qeadan, Fares et al.

EClinicalMedicine, Volume 0, Issue 0, 100938 


Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study. 

Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. 

J Subst Abuse Treat. 2021 Mar 19;129:108374. doi: 10.1016/j.jsat.2021.108374. Epub ahead of print. Erratum in: J Subst Abuse Treat. 2021 May 18;129:108427. PMID: 34080545.


The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic. 

Kosten TR, Petrakis IL. 

JAMA Psychiatry. 2021;78(6):585–586. doi:10.1001/jamapsychiatry.


Remote buprenorphine-naloxone initiation as an essential service for people with chronic pain and opioid dependence during the COVID-19 pandemic: Case reports, clinical pathways, and implications for the future. 

Clarke H, Weinrib A, Kotteeswaran Y, Katz J, Yu A, Tanguay R.

Can J Pain. 2020 Sep 15;4(1):224-235. doi: 10.1080/24740527.2020.1795634. PMID: 33987501; PMCID: PMC7951165.


Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study. 

Khoury D, Preiss A, Geiger P, Anwar M, Conway KP. 

JMIR Public Health Surveill. 2021 May 27;7(5):e29298. doi: 10.2196/29298. PMID: 33999828; PMCID: PMC8163496.


Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. 

Gomes T, Kitchen SA, Murray R. 

JAMA Netw Open. 2021 May 3;4(5):e2112865. doi: 10.1001/jamanetworkopen.2021.12865. PMID: 34037734.


A real-world ten-week follow-up of the COVID outbreak in an outpatient drug clinic in Salamanca (Spain). 

Aguilar L, Vicente-Hernández B, Remón-Gallo D, García-Ullán L, Valriberas-Herrero I, Maciá-Casas A, Pérez-Madruga A, Garzón MÁ, Álvarez-Navares A, Roncero C. 

J Subst Abuse Treat. 2021 Jun;125:108303. doi: 10.1016/j.jsat.2021.108303. Epub 2021 Jan 26. PMID: 34016295; PMCID: PMC8065063.


Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey. 

Radfar SR, De Jong CAJ, Farhoudian A, Ebrahimi M, Rafei P, Vahidi M, Yunesian M, Kouimtsidis C, Arunogiri S, Massah O, Deylamizadeh A, Brady KT, Busse A; ISAM-PPIG Global Survey Consortium, Potenza MN, Ekhtiari H, Baldacchino AM. 

Front Psychiatry. 2021 Apr 29;12:639393. doi: 10.3389/fpsyt.2021.639393. PMID: 34025471; PMCID: PMC8135096.


How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic. 

Pines JM, Zocchi MS, Black BS, Carlson JN, Celedon P, Moghtaderi A, Venkat A.

J Subst Abuse Treat. 2021 Apr 9;129:108391. doi: 10.1016/j.jsat.2021.108391. Epub ahead of print. PMID: 33994360.


Coping With Craving and Withdrawal Due to Substance Use Disorders During the COVID-19 Lockdown. 

Sidana A, Chavan BS, Rohilla R, Singh J. 

Prim Care Companion CNS Disord. 2021 Feb 24;23(2):20m02802. doi: 10.4088/PCC.20m02802. PMID: 34000123.


Challenges in methadone dispensing during Covid-19: An innovative approach using videocall based services. 

Arya S, Aggarwal N, Kumar V, Rathee S, Rani M, Madaan N, Malik G, Gupta R. Challenges 

Asian J Psychiatr. 2021 May 15;61:102675. doi: 10.1016/j.ajp.2021.102675. Epub ahead of print. PMID: 34022511; PMCID: PMC8123371.


Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. 

Hser YI, Ober AJ, Dopp AR, Lin C, Osterhage KP, Clingan SE, Mooney LJ, Curtis ME, Marsch LA, McLeman B, Hichborn E, Lester LS, Baldwin LM, Liu Y, Jacobs P, Saxon AJ. 

Addict Sci Clin Pract. 2021 Apr 20;16(1):24. doi: 10.1186/s13722-021-00233-x. PMID: 33879260; PMCID: PMC8056373.


COVID-19 Impact on Healthcare and Supportive Services for People Who Use Drugs (PWUDs) in Malaysia. 

Vicknasingam B, Mohd Salleh NA, Chooi WT, Singh D, Mohd Zaharim N, Kamarulzaman A, Chawarski MC. 

Front Psychiatry. 2021 Mar 29;12:630730. doi: 10.3389/fpsyt.2021.630730. PMID: 33854449; PMCID: PMC8039131.


Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic. 

Currie JM, Schnell MK, Schwandt H, Zhang J. 

JAMA Netw Open. 2021 Apr 1;4(4):e216147. doi: 10.1001/jamanetworkopen.2021.6147. PMID: 33856474; PMCID: PMC8050741.


Persons with Substance Abuse Disorders and Other Addictions: Coping with the COVID-19 Pandemic. (Kuba)

Fabelo-Roche JR, Iglesias-Moré S, Gómez-García AM. 

MEDICC Rev. 2021 Apr;23(2):10. doi: 10.37757/MR2021.V23.N2.2. Epub 2021 Apr 14. PMID: 33974609.


USA. Extended Take-homes: More Good News in New York

The expansion of methadone take-homes was highlighted as a positive move in New York by Governor Andrew Cuomo in his State of the State message January 11. This is a huge accomplishment, and one that other states should pick up on. In addition, he focused in general on increasing the availability of medication assisted treatment, which includes buprenorphine. (ATF – Addiction Treatment Forum, USA, 12.02.2021)


Drug Overdose Deaths Before and After Shelter-in-Place Orders During the COVID-19 Pandemic in San Francisco. 

Appa A, Rodda LN, Cawley C, et al. 

JAMA Netw Open. 2021;4(5):e2110452. doi:10.1001/jamanetworkopen.2021.10452


USA-NY. One Year Into COVID, Methadone Deliveries Show the Way Forward

Created in the spring of 2020, the New York City Methadone Delivery System (MDS) was the first program of its kind in the country, a collaboration between the city’s Department of Health and Mental Hygiene (DOHMH) and the New York State Offices of Addiction Services and Supports (OASAS). (Filter, USA, 22.04.2021)


USA. Behavioral Health: Patient Access, Provider Claims Payment, and the Effects of the COVID-19 Pandemic

How has the need for and availability of services for mental health and substance use disorders changed during the COVID-19 pandemic?

Evidence suggests these conditions increased while access to care decreased.

Centers for Disease Control surveys found about 38% of respondents reported symptoms of anxiety or depression from April 2020 through Feb. 2021—up from about 11% in 2019

Emergency department visits for overdoses and suicide attempts from mid-March to mid-Oct. 2020 were up 36% and 26%, respectively, from 2019

Many behavioral health service providers reported increasing demand and decreasing staff sizes



Canada's Response to the Dual Public Health Crises: A Cautionary Tale. 

Krausz RM, Wong JSH, Westenberg JN, Choi F, Schütz CG, Jang KL. 

Can J Psychiatry. 2021 Apr;66(4):349-353. doi: 10.1177/0706743721993634. Epub 2021 Feb 11. PMID: 33567889; PMCID: PMC8044624.


Effect of Coronavirus Disease 2019 on the Psychology and Behavior of Patients on Methadone Maintenance Treatment in Wuhan, China: A Clinical Observational Study. 

Liu X, Jin X, Zhang Y, Zhang L, Li Y, Ma J. 

Front Psychiatry. 2021 Mar 30;12:653662. doi: 10.3389/fpsyt.2021.653662. PMID: 33859585; PMCID: PMC8042146.


Innovative Virtual Role-Play Simulations for Managing Substance Use Conversations: Pilot Study Results and Relevance During and After COVID-19. 

Albright G, Khalid N, Shockley K, Robinson K, Hughes K, Pace-Danley B. 

JMIR Form Res. 2021 Apr 11. doi: 10.2196/27164. Epub ahead of print. PMID: 33848972.


Leveraging Telehealth in the United States to Increase Access to Opioid Use Disorder Treatment in Pregnancy and Postpartum During the COVID-19 Pandemic. 

Guille C, McCauley JL, Moreland A. 

Am J Psychiatry. 2021 Apr 1;178(4):290-293. doi: 10.1176/appi.ajp.2020.20060949. PMID: 33789451; PMCID: PMC8023749.


Home delivery of legal intoxicants in the age of COVID-19. 

Matthay EC, Schmidt LA. 

Addiction. 2021 Apr;116(4):691-693. doi: 10.1111/add.15289. Epub 2020 Nov 26. PMID: 33047828; PMCID: PMC7675702.


Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic. 

Currie JM, Schnell MK, Schwandt H, Zhang J. 

JAMA Netw Open. 2021;4(4):e216147. doi:10.1001/jamanetworkopen.2021.6147


Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. 

Croxford S, Emanuel E, Ibitoye A, Njoroge J, Edmundson C, Bardsley M, Heinsbroek E, Hope V, Phipps E. 

Public Health. 2021 Mar;192:8-11. doi: 10.1016/j.puhe.2021.01.004. Epub 2021 Jan 15. PMID: 33601307; PMCID: PMC7836733.


Responding to COVID-19: Emerging Practices in Addiction Medicine in 17 Countries. 

Scheibein F, Stowe MJ, Arya S, Morgan N, Shirasaka T, Grandinetti P, Saad NA, Ghosh A, Vadivel R, Ratta-Apha W, Pant SB, Ransing R, Ramalho R, Bruschi A, Maiti T, Ha AY, Delic M, Jain S, Peyron E, Siste K, Onoria J, Boujraf S, Dannatt L, Schellekens A, Calvey T. 

Front Psychiatry. 2021 Mar 12;12:634309. doi: 10.3389/fpsyt.2021.634309. PMID: 33796034; PMCID: PMC8009036.